Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 21,200 shares, a drop of 18.5% from the May 15th total of 26,000 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average trading volume of 47,300 shares, the short-interest ratio is currently 0.4 days.
Synaptogenix Price Performance
SNPX traded down $0.05 during mid-day trading on Monday, reaching $4.56. 6,133 shares of the stock were exchanged, compared to its average volume of 42,662. The company has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $5.21. Synaptogenix has a 1 year low of $3.53 and a 1 year high of $47.00.
Synaptogenix (NASDAQ:SNPX – Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.41) earnings per share for the quarter.
About Synaptogenix
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Stories
- Five stocks we like better than Synaptogenix
- What is the Australian Securities Exchange (ASX)
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- Trading Halts Explained
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
- Overbought Stocks Explained: Should You Trade Them?
- Buy, Sell, or Hold: What to Do with AMC Entertainment Stock?
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.